Tom 4, Nr 4 (2019)
Artykuł przeglądowy
Opublikowany online: 2020-01-29
Wyświetlenia strony
1239
Wyświetlenia/pobrania artykułu
1412
Chlorek dekwaliniowy – atrakcyjna opcja terapeutyczna w leczeniu zakażeń pochwy
Ginekologia i Perinatologia Praktyczna 2019;4(4):155-159.
Streszczenie
Zakażenia pochwy są jedną z najczęstszych przyczyn wizyt w gabinetach ginekologicznych. Zaburzenia fizjologicznej
flory bakteryjnej pochwy prowadzą do rozwoju infekcji, których występowanie wiąże się z możliwością rozwoju
poważnych powikłań. Istotnymi problemami w codziennej praktyce są występowanie oporności na standardowe
leczenie oraz częste nawroty choroby. W pracy przedstawiono aktualny stan wiedzy oraz wytyczne dotyczące skuteczności
terapeutycznej i zastosowania w praktyce klinicznej chlorku dekwalinianu.
Słowa kluczowe: zakażenia pochwywaginoza bakteryjnachlorek dekwaliniowy
Referencje
- Fettweis JM, Brooks JP, Serrano MG, et al. Differences in vaginal microbiome in African American women versus women of European ancestry. Microbiology. 2014; 160(Pt 10): 2272–2282.
- Ma B, Forney LJ, Ravel J. Vaginal microbiome: rethinking health and disease. Annu Rev Microbiol. 2012; 66: 371–389.
- Badger J, Ng P, Venter J. The Human Genome, Microbiomes, and Disease. Metagenomics of the Human Body. 2010: 1–14.
- Sieroszewski P, Bober Ł, Kłosiński W. Zakażenia podczas ciąży. Perinat Neonatol Ginekol. 2012; 5: 65–84.
- Donders GGG. Definition and classification of abnormal vaginal flora. Best Pract Res Clin Obstet Gynaecol. 2007; 21(3): 355–373.
- Mårdh PA, Rodrigues AG, Genç M, et al. Facts and myths on recurrent vulvovaginal candidosis--a review on epidemiology, clinical manifestations, diagnosis, pathogenesis and therapy. Int J STD AIDS. 2002; 13(8): 522–539.
- Romanik M, Ekiel A, Tomana L, et al. Waginoza bakteryjna - problemy w terapii. Wiadomości Lekarskie. 2007; 60: 64–67.
- Han C, Li H, Han L, et al. Aerobic vaginitis in late pregnancy and outcomes of pregnancy. Eur J Clin Microbiol Infect Dis. 2019; 38(2): 233–239.
- Karasz A, Anderson M. The vaginitis monologues: women's experiences of vaginal complaints in a primary care setting. Soc Sci Med. 2003; 56(5): 1013–1021.
- Bilardi JE, Walker S, Temple-Smith M, et al. The burden of bacterial vaginosis: women's experience of the physical, emotional, sexual and social impact of living with recurrent bacterial vaginosis. PLoS One. 2013; 8(9): e74378.
- Palmeira-de-Oliveira R, Palmeira-de-Oliveira A, Martinez-de-Oliveira J. New strategies for local treatment of vaginal infections. Adv Drug Deliv Rev. 2015; 92: 105–122.
- Wielgoś M, Pietrzak B. Bacterial vaginosis: diagnosis and treatment. Menopausal Review. 2012; 5: 356–363.
- Sobel J. Bacterial Vaginosis. Annual Review of Medicine. 2000; 51(1): 349–356.
- Sobel JD. Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol. 1985; 152(7 Pt 2): 924–935.
- Cook RL, Downs JS, Marrazzo J, et al. Preferred characteristics of vaginal microbicides in women with bacterial vaginosis. J Womens Health (Larchmt). 2009; 18(8): 1163–1167.
- Biggs W, Williams R. Common Gynecologic Infections. Primary Care: Clinics in Office Practice. 2009; 36(1): 33–51.
- Forsum U, Holst E, Larsson PG, et al. Bacterial vaginosis--a microbiological and immunological enigma. APMIS. 2005; 113(2): 81–90.
- Goldstein EJ, Citron DM, Cherubin CE, et al. Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole. J Antimicrob Chemother. 1993; 31(3): 363–372.
- Goldstein EJC, Citron DM, Merriam CV, et al. In vitro activities of Garenoxacin (BMS 284756) against 108 clinical isolates of Gardnerella vaginalis. Antimicrob Agents Chemother. 2002; 46(12): 3995–3996.
- Srinivasan S, Fredricks DN. The human vaginal bacterial biota and bacterial vaginosis. Interdiscip Perspect Infect Dis. 2008; 2008: 750479.
- Polatti F. Bacterial vaginosis, Atopobium vaginae and nifuratel. Curr Clin Pharmacol. 2012; 7(1): 36–40.
- Sobel J. Vulvovaginal candidosis. The Lancet. 2007; 369(9577): 1961–1971.
- Tietz HJ. Therapy problems in chronic recurrent vaginal mycosis. Ther Umsch. 2002; 59(9): 481–484.
- Cleveland A. Vaginitis: finding the cause prevents treatment failure. Cleve Clin J Med. 2000; 67(9): 634, 637–642, 645.
- Marrazzo J. Vulvovaginal candidiasis. BMJ. 2003; 326(7397): 993–994.
- Sherrard J, Wilson J, Donders G, et al. 2018 European (IUSTI/WHO) International Union against sexually transmitted infections (IUSTI) World Health Organisation (WHO) guideline on the management of vaginal discharge. Int J STD AIDS. 2018; 29(13): 1258–1272.
- D’Auria F, Simonetti G, Strippoli V. Caratteristiche antimicrobiche di una tintura al dequalinio cloruro. Ann Ig. 1989; 1: 1227–1241.
- Della Casa V, Noll H, Gonser S, et al. Antimicrobial activity of dequalinium chloride against leading germs of vaginal infections. Arzneimittelforschung. 2002; 52(9): 699–705.
- Tischer M, Pradel G, Ohlsen K, et al. Quaternary ammonium salts and their antimicrobial potential: targets or nonspecific interactions? ChemMedChem. 2012; 7(1): 22–31.
- Block SS. Disinfection, Sterilization, and Preservation. Soil Science. 1977; 124(6): 378.
- Hugo WB, Frier M. Mode of action of the antibacterial compound dequalinium acetate. Appl Microbiol. 1969; 17(1): 118–127.
- Lopes dos Santos Santiago G, Grob P, Verstraelen H, et al. Susceptibility testing of Atopobium vaginae for dequalinium chloride. BMC Res Notes. 2012; 5: 151.
- Mendling W, Palmeira-de-Oliveira A, Biber S, et al. An update on the role of Atopobium vaginae in bacterial vaginosis: what to consider when choosing a treatment? A mini review. Arch Gynecol Obstet. 2019; 300(1): 1–6.
- Turner RJ, Taylor DE, Weiner JH. Expression of Escherichia coli TehA gives resistance to antiseptics and disinfectants similar to that conferred by multidrug resistance efflux pumps. Antimicrob Agents Chemother. 1997; 41(2): 440–444.
- Ali-Melkkilä T, Kaila T, Kanto J. Glycopyrrolate: pharmacokinetics and some pharmacodynamic findings. Acta Anaesthesiol Scand. 1989; 33(6): 513–517.
- Liebmann B, Henke D, Spahn-Langguth H, et al. Determination of the quaternary compound ciclotropium in human biological material after hydrolysis and derivatization with the fluorophor flunoxaprofen chloride. J Chromatogr. 1991; 572(1-2): 181–193.
- Schladitz-Keil G, Spahn H, Mutschler E. Determination of the bioavailability of the quaternary compound trospium chloride in man from urinary excretion data. Arzneimittelforschung. 1986; 36(6): 984–987.
- Petersen E, Weissenbacher E, Hengst P, et al. Local Treatment of Vaginal Infections of Varying Etiology with Dequalinium Chloride or Povidone Iodine. Arzneimittelforschung. 2011; 52(09): 706–715.
- Weissenbacher ER, Donders G, Unzeitig V, et al. Fluomizin Study Group. A comparison of dequalinium chloride vaginal tablets (Fluomizin®) and clindamycin vaginal cream in the treatment of bacterial vaginosis: a single-blind, randomized clinical trial of efficacy and safety. Gynecol Obstet Invest. 2012; 73(1): 8–15.
- Strecker M, Kokemohr H, Teucher T, et al. Antiseptika gegen vulvovaginitiden. TW Gynäkologie. 1993; 6: 409–412.
- Radzinsky V, Ordiyants I, Chetvertakova E, et al. Two Stage therapy for Vaginal Infections. Akusherstvo i Ginekologiia. 2011; 5: 78–81.
- Mendling W, Martius J, Hoyme U. S1-Guideline on Bacterial Vaginosis in Gynecology and Obstetrics. Geburtshilfe und Frauenheilkunde. 2014; 74(01): 51–54.
- SPG - Sociedade Portuguesa De Ginecologia. http://www.spginecologia.pt.
- http://www.somersetccg.nhs.uk/EasySiteWeb/GatewayLink.aspx?alId=6573.
- https://www.scottishmedicines.org.uk/media/1551/dequalinium_fluomizin_final_oct_2016_amended_311016_for_website.pdf..
- All Wales Medicines Strategy Group. The Pharmaceutical Journal. 2014.
- Guía Práctica de Asistencia S.E.G.O: Diagnóstico y tratamiento de las infecciones vulvovaginales Actualizado 2018. Madrid. Sociedad Española de Obstetricia y Ginecología. Enero 2018 Tratamientos actualizados y consensuados para las Infecciones de Transmisión Sexual.
- Mendling W, Weissenbacher ER, Gerber S, et al. Use of locally delivered dequalinium chloride in the treatment of vaginal infections: a review. Arch Gynecol Obstet. 2016; 293(3): 469–484.
- Dankovich D, Gopchuk E. New opportunities in preparation of women with reproductive tracts microbiocenosis disorder for gynaecologic intervention. Women’s Health. 2006; 2(26): 1–4.
- Charakterystyka produktu leczniczego Fluomizin.
- Hijona JJ, Carballo AL, Sánchez MS, et al. Vaginal antiseptics reduce the risk of perinatal infection with group B streptococci. J Matern Fetal Neonatal Med. 2019; 32(16): 2741–2745.
